Background: Ivacaftor shows benefit in patients with cystic fibrosis (CF) and CFTR mutations associated with residual CF transmembrane conductance regulator (CFTR) function. Here we further assess the effect of ivacaftor in such patients using an N-of-1 study design.
Methods: Patients aged ≥12 years with CF with clinical or molecular evidence of residual CFTR function were randomized to 1 of 4 treatment sequences for two 4-week, double-blind crossover cycles (each divided into 2 weeks of ivacaftor treatment and placebo) followed by 8 weeks of open-label ivacaftor treatment. The primary endpoint was absolute change from cycle baseline of percent predicted forced expiratory volume in 1 s (ppFEV1) after 2 weeks of treatment with ivacaftor relative to placebo.
Results: Absolute change (SD) from study baseline in ppFEV1 favored ivacaftor by 2.3 (1.0) percentage points (95% credible interval, 0.4-4.1) after 2 weeks of treatment. Absolute mean change (SD) from open-label baseline (defined as day 1 of the open-label ivacaftor treatment period) in ppFEV1 after 8 weeks of treatment was 4.7 (4.2) percentage points (P<.0001). Safety of ivacaftor was consistent with that observed in prior studies.
Conclusions: Ivacaftor improved lung function during the double-blind and open-label treatment periods in patients with CF and CFTR mutations associated with residual CFTR function (ClinicalTrials.gov, NCT01685801).
Keywords: Bayesian hierarchical model; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Forced expiratory volume; Ivacaftor; Residual CFTR function.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.
Efficacy and Safety of Lumacaftor/Ivacaftor Combination Therapy in Patients With Cystic Fibrosis Homozygous for Phe508del CFTR by Pulmonary Function Subgroup: A Pooled AnalysisJS Elborn et al. Lancet Respir Med 4 (8), 617-626. PMID 27298017. - Meta-AnalysisVertex Pharmaceuticals.
Efficacy and Safety of Lumacaftor and Ivacaftor in Patients Aged 6-11 Years With Cystic Fibrosis Homozygous for F508del-CFTR: A Randomised, Placebo-Controlled Phase 3 TrialF Ratjen et al. Lancet Respir Med 5 (7), 557-567. PMID 28606620. - Clinical TrialVertex Pharmaceuticals.
Efficacy and Safety of Ivacaftor in Patients With Cystic Fibrosis Who Have an Arg117His-CFTR Mutation: A Double-Blind, Randomised Controlled TrialRB Moss et al. Lancet Respir Med 3 (7), 524-33. PMID 26070913. - Clinical TrialVertex Pharmaceuticals Incorporated.
Correctors (Specific Therapies for Class II CFTR Mutations) for Cystic FibrosisKW Southern et al. Cochrane Database Syst Rev 8 (8), CD010966. PMID 30070364. - ReviewThere is insufficient evidence that monotherapy with correctors has clinically important effects in people with CF who have two copies of the F508del mutation.Combination …
Potentiators (Specific Therapies for Class III and IV Mutations) for Cystic FibrosisS Patel et al. Cochrane Database Syst Rev (3), CD009841. PMID 25811419. - ReviewBoth G551D phase 3 trials (n = 219) demonstrated a clinically relevant impact of the potentiator ivacaftor on outcomes at 24 and 48 weeks, providing evidence for the use …